Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
|
|
Odonate Therapeutics, Inc. (ODT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/14/2022 |
SC 13G/A
| Ikarian Capital, LLC reports a 3.5% stake in Odonate Therapeutics, Inc. |
| 02/10/2022 |
SC 13G/A
| JANUS HENDERSON GROUP PLC reports a 0% stake in Odonate Therapeutics, Inc. |
| 02/07/2022 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 01/31/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/31/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/31/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/28/2022 |
SC 13G/A
| BML Investment Partners, L.P. reports a 7.4% stake in Odonate Therapeutics Inc |
| 01/28/2022 |
SC 13G
| BML Investment Partners, L.P. reports a 7.4% stake in Odonate Therapeutics Inc |
| 01/26/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 01/26/2022 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 01/26/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 01/26/2022 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 01/26/2022 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 01/25/2022 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 01/07/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and... |
| 12/10/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/10/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 11/26/2021 |
SC 13D/A
| Boxer Capital, LLC reports a 10.9% stake in Odonate Therapeutics, Inc. |
| 11/24/2021 |
4
| Boxer Capital, LLC (10% Owner) has filed a Form 4 on Odonate Therapeutics, Inc.|
Txns:
| Sold 200,000 shares
@ $1.5483, valued at
$309.7k
Sold 200,000 shares
@ $1.5684, valued at
$313.7k
|
|
| 11/22/2021 |
SC 13D/A
| Boxer Capital, LLC reports a 12% stake in Odonate Therapeutics, Inc. |
| 11/19/2021 |
4
| Davis Aaron I. (10% Owner) has filed a Form 4 on Odonate Therapeutics, Inc.|
Txns:
| Sold 170,000 shares
@ $2.2334, valued at
$379.7k
Sold 600,000 shares
@ $2.1654, valued at
$1.3M
Sold 250,000 shares
@ $1.949, valued at
$487.3k
Sold 30,000 shares
@ $1.9165, valued at
$57.5k
Sold 150,000 shares
@ $1.8419, valued at
$276.3k
|
|
| 11/19/2021 |
4
| Boxer Capital, LLC (10% Owner) has filed a Form 4 on Odonate Therapeutics, Inc.|
Txns:
| Sold 600,000 shares
@ $2.1654, valued at
$1.3M
Sold 250,000 shares
@ $1.949, valued at
$487.3k
Sold 150,000 shares
@ $1.8419, valued at
$276.3k
|
|
| 11/19/2021 |
SC 13D/A
| TANG CAPITAL PARTNERS LP reports a 33.7% stake in Odonate Therapeutics, Inc. |
| 11/19/2021 |
4
| TANG KEVIN C (CEO) has filed a Form 4 on Odonate Therapeutics, Inc.|
Txns:
| Sold 468,849 shares
@ $2.6583, valued at
$1.2M
Sold 31,151 shares
@ $1.9941, valued at
$62.1k
Sold 500,000 shares
@ $2.0161, valued at
$1M
Sold 287,577 shares
@ $2.1985, valued at
$632.2k
Sold 212,423 shares
@ $1.9708, valued at
$418.6k
Sold 500,000 shares
@ $1.8812, valued at
$940.6k
Sold 381,842 shares
@ $1.8925, valued at
$722.6k
Sold 365,289 shares
@ $1.9161, valued at
$699.9k
|
|
| 11/18/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 11/18/2021 |
SC 13G/A
| EcoR1 Capital, LLC reports a 14.8% stake in Odonate Therapeutics, Inc. |
| 11/18/2021 |
3
| EcoR1 Capital, LLC (10% Owner) has filed a Form 3 on Odonate Therapeutics, Inc. |
| 11/10/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
| 08/05/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/27/2021 |
10-Q
| Quarterly Report for the period ended June 30, 2021 |
| 07/19/2021 |
SC 13G
| EcoR1 Capital, LLC reports a 8.7% stake in Odonate Therapeutics, Inc. |
| 07/02/2021 |
SC 13G
| Ikarian Capital, LLC reports a 5.2% stake in Odonate Therapeutics, Inc. |
| 06/25/2021 |
8-K
| Quarterly results |
| 06/01/2021 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
|
|
|